Promising lung cancer combo trial pulled before starting
NCT ID NCT06713798
First seen Apr 03, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study was designed to test whether adding tiragolumab to atezolizumab works better than atezolizumab alone for people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. It planned to include patients who had not received prior treatment and those who had already tried immunotherapy. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.